---
schema_version: "secwatch.filing_event.v1"
accession: "0001740797-23-000069"
form_type: "8-K"
ticker: "AVAI"
cik: "0001740797"
company_name: "AVAI BIO, INC."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T06:59:09.613946+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avant signs $375K/quarter advisor deal with Timothy Lantz for product & market strategy

## Summary
- Timothy Lantz appointed Chief Product & Market Strategy Advisor effective Aug 1, 2023; receives $375K quarterly (40% cash min, rest in stock at 15% VWAP discount, floor $0.10).
- If Avant lists on Nasdaq, quarterly fee increases to $450K retroactive to Aug 1, 2023; payments then in cash.
- Term runs Aug 1, 2023 to July 31, 2024, extendable by mutual consent; 30-day termination for convenience by either party.
- Advisor currently serves as senior executive at a private AI/tech company; agreement acknowledges outside work.
- Shares issued are unregistered; advisor accredited investor.

## SEC filing metadata
- accession: 0001740797-23-000069
- form_type: 8-K
- ticker: AVAI
- cik: 0001740797
- company_name: AVAI BIO, INC.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000069/0001740797-23-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740797/000174079723000069/avai_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001740797-23-000069
- JSON: https://secwatch.observer/filing/0001740797-23-000069.json
- Plain text: https://secwatch.observer/filing/0001740797-23-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.